Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric03 in HER2-expressing advanced gastric/GEJ/esophageal adenocarcinoma
CTR20213371Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate. Started May 2022; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20213371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213371.